← Back to Clinical Trials
Recruiting Phase 4 NCT06819436

NCT06819436 Effect of Dexamethasone on Post-spinal Hypotension

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06819436
Status Recruiting
Phase Phase 4
Sponsor Shaheed Mohtarma Benazir Bhutto Institue of Trauma
Condition Post Spinal Anaesthesia Hypotension
Study Type INTERVENTIONAL
Enrollment 170 participants
Start Date 2025-02
Primary Completion 2025-04

Eligibility & Interventions

Sex All sexes
Min Age 65 Years
Max Age 85 Years
Study Type INTERVENTIONAL
Interventions
DexamethasonePlacebo

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.

This trial targets 170 participants in total. It began in 2025-02 with a primary completion date of 2025-04.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this clinical trial is to learn if intravenous dexamethasone is effective for prevention of post spinal hypotension in geriatric population undergoing orthopedic surgeries. The main question aim to answer is: Does intravenous dexamethasone in participants undergoing orthopedic procedures of lower limb under spinal anesthesia prevents post spinal hypotension? Researchers are comparing two groups of participants * Participants in (Dexamethasone Group) Group D are receiving intravenous dexamethasone 8mg preoperatively * Participants in (Placebo Group) Group P are receiving placebo preoperatively.

Eligibility Criteria

Inclusion Criteria: Patient undergoing orthopedic surgery in spinal anesthesia. ASA ≤ 2. Exclusion Criteria: Patients with history of cardiac arrhythmias. Patients with history of acute coronary syndrome. Patient with history of polytrauma. Patients with contraindication to SA (e.g., coagulopathy, thrombocytopenia, allergy to local anesthetic agent) and those on steroids or serotonin related medications (e.g., selective serotonin reuptake inhibitor) will be excluded.

Contact & Investigator

Central Contact

Sidra Javed, MBBS, FCPS, Pain fellow

✉ sidra_dow@yahoo.com

📞 +92333 2474831

Frequently Asked Questions

Who can join the NCT06819436 clinical trial?

This trial is open to participants of all sexes, aged 65 Years or older, up to 85 Years, studying Post Spinal Anaesthesia Hypotension. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

What phase is the NCT06819436 trial and what does that mean for participants?

Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.

Is NCT06819436 currently recruiting?

Yes, NCT06819436 is actively recruiting participants. Contact the research team at sidra_dow@yahoo.com for enrollment information.

Where is the NCT06819436 trial being conducted?

This trial is being conducted at Karachi, Pakistan.

Who is sponsoring the NCT06819436 clinical trial?

NCT06819436 is sponsored by Shaheed Mohtarma Benazir Bhutto Institue of Trauma. The trial plans to enroll 170 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology